New appointment at Takeda Pharmaceuticals Europe
This article was originally published in Scrip
Dr Erich Brunn has been appointed CEO ofTakeda Pharmaceuticals Europe. The UK subsidiary oversees sales and marketing activities conducted through six subsidiaries across Europe for Takeda, Japan's largest pharmaceuticals firm. Dr Brunn was previously president of Takeda Pharma in Germany.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.